FDA OKs New Videx Formulation
A new 200 mg formulation of Videx (ddI, didanosine) to be used once a day has been approved by the Food and Drug Administration and is expected to be available in December.
People with HIV infection can now take two tablets once a day as opposed to the current formulation which calls for two tablets twice a day. Videx is the first nucleoside reverse transcriptase inhibitor on the market to be used once daily.
Since the dosing is now once a day, better adherence to this medication is expected.
A buffer in the old Videx formulation helped with absorption of the drug and required that it be taken half an hour before a meal or an hour after a meal. Because the prior formulation of Videx caused gastrointestinal (GI) problems, this has been a problem for some. The new formulation, however, includes less of the buffer since the chemical composition of the drug has been changed. Fewer GI problems are expected to be associated with the new formulation.
This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).
This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.